Biotech firms bet on Hong Kong for regional headquarters

    Biotech firms bet on Hong Kong for regional headquarters

    Visitors look at new buildings in Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone on Dec 22, 2025. (ADAM LAM / CHINA DAILY) At least 17 international biotechnology companies have established operations in Hong Kong this year, with several having set up Asia-Pacific headquarters in the city — drawn…

    Read More
    STAT+

      China’s rapid ascent is reshaping drug development

      Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The NIH’s foreign subaward crackdown is scrambling global collaborations, while China’s rapid ascent is reshaping drug development. Meanwhile, Wave Life Sciences sheds half its value on underwhelming obesity results. Also, breaking: I’m adopting a rogue…

      Read More
      China and Hong Kong should relax biotech listing rules, venture capitalist says

        China and Hong Kong should relax biotech listing rules, venture capitalist says

        Mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalise on renewed foreign interest in the healthcare sector, venture capitalist Nisa Leung said. “Besides artificial intelligence, Premier Li Qiang also highlighted biomedicine in the ‘two sessions’ annual government work report,” said Leung, a managing…

        Read More
        Stephen Luo, Jingtian & Gongcheng

          Capital market reforms, investment trends in Hong Kong and Taiwan

          Hong Kong IPOs 2025: Market views, mega deals, emerging trends Hong Kong cemented its status as the world’s leading initial public offerings venue in 2025, marking a year of momentum, progress and transformation. By mid-December, the market had raised HKD274.6 billion (USD35.2 billion) from 106 new listings, with four of the world’s top 10 IPOs…

          Read More
          STAT+

            China biopharma, JP Morgan 2026: Readout Newsletter

            Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s an exciting week not only for biotech M&A, but also for my city (Chicago) as we gear up for our big game this Saturday. Going into JPM, it’s good to be a…

            Read More
            HUTCHMED gains wider China drug coverage on NRDL, insurance

              Adlai Nortye (ANL) licenses AN9025 to ASK Pharm in Greater China

              Adlai Nortye (NASDAQ: ANL) entered an exclusive license agreement with ASK Pharm for its pan‑RAS (ON) inhibitor AN9025 in mainland China, Hong Kong and Macao on Dec 29, 2025. ASK Pharm gains rights to develop, manufacture, and commercialize AN9025 in the Licensed Territory while Adlai Nortye retains worldwide rights elsewhere. The deal…

              Read More
              Sen. Mark Warner on a Chinese tech threat that will be bigger than Huawei

                Why senator says US should spy more on China’s companies

                Go back a decade and most Americans had never heard of Huawei. Today, the Chinese telecom giant is a symbol of how quickly China can dominate a strategic technology sector and in the process create new national security and market threats for U.S. government and industry. Democratic Senator Mark Warner of Virginia, the top Democrat…

                Read More